Literature DB >> 31922192

Characterization and applications of Type I CRISPR-Cas systems.

Claudio Hidalgo-Cantabrana1, Rodolphe Barrangou1.   

Abstract

CRISPR-Cas constitutes the adaptive immune system of bacteria and archaea. This RNA-mediated sequence-specific recognition and targeting machinery has been used broadly for diverse applications in a wide range of organisms across the tree of life. The compact class 2 systems, that hinge on a single Cas effector nuclease have been harnessed for genome editing, transcriptional regulation, detection, imaging and other applications, in different research areas. However, most of the CRISPR-Cas systems belong to class 1, and the molecular machinery of the most widespread and diverse Type I systems afford tremendous opportunities for a broad range of applications. These highly abundant systems rely on a multi-protein effector complex, the CRISPR associated complex for antiviral defense (Cascade), which drives DNA targeting and cleavage. The complexity of these systems has somewhat hindered their widespread usage, but the pool of thousands of diverse Type I CRISPR-Cas systems opens new avenues for CRISPR-based applications in bacteria, archaea and eukaryotes. Here, we describe the features and mechanism of action of Type I CRISPR-Cas systems, illustrate how endogenous systems can be reprogrammed to target the host genome and perform genome editing and transcriptional regulation by co-delivering a minimal CRISPR array together with a repair template. Moreover, we discuss how these systems can also be used in eukaryotes. This review provides a framework for expanding the CRISPR toolbox, and repurposing the most abundant CRISPR-Cas systems for a wide range of applications.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Keywords:  CRISPR; Cas; Type I; genome editing

Year:  2020        PMID: 31922192     DOI: 10.1042/BST20190119

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  12 in total

1.  A TXTL-Based Assay to Rapidly Identify PAMs for CRISPR-Cas Systems with Multi-Protein Effector Complexes.

Authors:  Franziska Wimmer; Frank Englert; Chase L Beisel
Journal:  Methods Mol Biol       Date:  2022

Review 2.  CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses.

Authors:  Qun Wu; Luqing Cui; Yingying Liu; Rongpeng Li; Menghong Dai; Zhenwei Xia; Min Wu
Journal:  Mol Biomed       Date:  2022-07-20

3.  The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases.

Authors:  Juan Lou; Bin Wang; Junwei Li; Peng Ni; Yuefei Jin; Shuaiyin Chen; Yuanlin Xi; Rongguang Zhang; Guangcai Duan
Journal:  Mol Biol Rep       Date:  2022-07-20       Impact factor: 2.742

4.  A compact Cascade-Cas3 system for targeted genome engineering.

Authors:  Bálint Csörgő; Lina M León; Ilea J Chau-Ly; Alejandro Vasquez-Rifo; Joel D Berry; Caroline Mahendra; Emily D Crawford; Jennifer D Lewis; Joseph Bondy-Denomy
Journal:  Nat Methods       Date:  2020-10-19       Impact factor: 28.547

5.  Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.

Authors:  Renke Tan; Ryan K Krueger; Max J Gramelspacher; Xufei Zhou; Yibei Xiao; Ailong Ke; Zhonggang Hou; Yan Zhang
Journal:  Mol Cell       Date:  2022-01-19       Impact factor: 17.970

Review 6.  CRISPR technologies and the search for the PAM-free nuclease.

Authors:  Daphne Collias; Chase L Beisel
Journal:  Nat Commun       Date:  2021-01-22       Impact factor: 14.919

7.  CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus.

Authors:  Kazuto Yoshimi; Kohei Takeshita; Seiya Yamayoshi; Satomi Shibumura; Yuko Yamauchi; Masaki Yamamoto; Hiroshi Yotsuyanagi; Yoshihiro Kawaoka; Tomoji Mashimo
Journal:  iScience       Date:  2022-01-30

8.  Structural basis of cyclic oligoadenylate binding to the transcription factor Csa3 outlines cross talk between type III and type I CRISPR systems.

Authors:  Pengjun Xia; Anirudha Dutta; Kushol Gupta; Mona Batish; Vijay Parashar
Journal:  J Biol Chem       Date:  2022-01-14       Impact factor: 5.157

Review 9.  Novel genetic therapeutic approaches for modulating the severity of β-thalassemia (Review).

Authors:  Fareeha Amjad; Tamseel Fatima; Tuba Fayyaz; Muhammad Aslam Khan; Muhammad Imran Qadeer
Journal:  Biomed Rep       Date:  2020-09-02

Review 10.  CRISPR-Cas9 DNA Base-Editing and Prime-Editing.

Authors:  Ariel Kantor; Michelle E McClements; Robert E MacLaren
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.